GlassScriptPhysician profile
Milan Patel
NPI 1679101935
$2,118.38
in general payments reported to CMS, 2019-2025
12 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.31 · 2024: $572 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194 · Travel and Lodging: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.98 |
| Travel and Lodging | $924.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,500.26 | 2024-2025 | Optablate, Spinejack, Flowtriever |
| Novo Nordisk INC | $166.66 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $90.68 | 2023-2025 | Shingrix, Arexvy |
| Pfizer INC. | $86.48 | 2024-2025 | |
| Angiodynamics, INC. | $55.91 | 2025 | Alphavac |
| Lilly USA, LLC | $53.10 | 2024-2025 | Jardiance, Zepbound |
| Boston Scientific Corporation | $48.68 | 2024 | Obsidio |
| Astrazeneca Pharmaceuticals LP | $35.50 | 2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $31.98 | 2024-2025 | |
| Abbott Laboratories | $20.26 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $15.54 | 2024 | Krystexxa |
| Merck Sharp & Dohme LLC | $13.33 | 2024 | Gardasil 9, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.